Manuscript title: Facilitators and barriers to cotrimoxazole prophylaxis among HIV exposed babies: a qualitative study from Harare, Zimbabwe
© Sibanda et al. 2015
Received: 3 March 2015
Accepted: 10 August 2015
Published: 15 August 2015
Implementation of cotrimoxazole prophylaxis (CTX-p) among HIV-exposed infants (HEI) is poor in southern Africa. We conducted a study to investigate barriers to delivery of CTX-p to HEI in Zimbabwe at each step of the care cascade. Here we report findings of the qualitative component designed to investigate issues related to adherence conducted among women identified as HIV positive whose babies were started on CTX-p postnatally. Of note, Zimbabwe also provided nevirapine prophylaxis for HIV exposed babies, so the majority were giving nevirapine and CTX-p to their babies.
Between Feb–Dec 2011, the first 20 HIV infected mothers identified were invited for in-depth interview 4–5months postnatally. Interviews were recorded, transcribed, translated and analysed thematically.
All women desired their baby’s health above all else, and were determined to do all they could to ensure their wellbeing. They did not report problems remembering to give drugs. The baby’s apparent good health was a huge motivator for continued adherence. However, most women reported that their husbands were less engaged in HIV care, refusing to be HIV tested and in some cases stealing drugs prescribed for their wives for themselves. In two instances the man stopped the woman from giving CTX-p to the baby either because of fear of side effects or not appreciating its importance. Stigma continues to be an important issue. Mothers reported being reluctant to disclose their HIV status to other people so found it difficult to collect prescription refills from the HIV clinic for fear of being seen by friends/relatives. Some women reported that it was hard to administer the drugs if there were people around at home. Other challenges faced were stock-outs of CTX-p at the clinic, which occurred three times in 2011. The baby would then go without CTX-p if the woman could not afford buying at a private pharmacy.
The study highlights that adherence knowledge and desire alone is insufficient to overcome the familial and structural barriers to maintaining CTX-p. Improving adherence to CTX-p among HEI will require interventions to improve male involvement, reduce HIV stigma in communities and ensure adequate supply of drugs.
Infants born to HIV infected mothers (HIV-exposed infants, HEI) are at risk of mother-to-child transmission of HIV during pregnancy, delivery and breastfeeding. There is also evidence that HEI suffer more morbidity and mortality than infants born to HIV negative mothers likely due to 1) greater exposure to infection agents, 2) poor nutrition and care as a result of the mother’s illness or death [1–3]; and 3) altered innate immunity which could be mediated by exposure to HIV in utero and early in life or exposure to maternal antiretroviral drugs during prevention of mother to child transmission (PMTCT) [4, 5]. Many interventions have been introduced to prevent mother-to-child transmission of HIV and/or opportunistic infections among both HIV-infected and uninfected HEI. These include ARV prophylaxis and/or treatment regimens for the mother and infant that are given for various lengths of time depending on the infant feeding method and the WHO guideline that the PMTCT programme has adopted. Those programmes adopting Option B/B+ guidelines advise HEI to take ARV prophylaxis for the first 4–6 weeks of life, but those adopting Option A recommend that infants continue on nevirapine prophylaxis until one week after cessation of breastfeeding [6, 7]. In addition, all HEI in generalised HIV epidemics should take cotrimoxazole prophylaxis (CTX-p) from the first 4–6 weeks of life and continue until HIV infection can be excluded . This means mothers and carers need to devote attention and care in ensuring adherence to these life-saving pharmacological interventions.
Unfortunately, current literature shows an unacceptable loss to follow up of infants along the PMTCT cascade [9, 10]. A recent systematic review estimated that 34 % of infants in Sub-Saharan Africa are lost to follow up from real-life PMTCT programs by three months of age, and 45 % are lost after HIV testing . In Zimbabwe, retention of HEI has been a challenge since inception of PMTCT services. In 2007, only 11 % of infants who needed CTX-p received it  increasing to 34 % in 2010  and 55 % in 2012 . Studies have been done to explore barriers to retention of HEI along the PMTCT cascade from the carer’s perspective [15–17], and these include intrapersonal barriers such as fear that the infant will test HIV positive, spiritual and traditional beliefs, disbelief that PMTCT interventions work, time and money constraints and fear of disclosure of HIV status; interpersonal and community e.g. unsupportive male partners, stigmatising attitudes from family and community; health care system e.g. unfriendly health care workers, long queues and waiting times and different appointments for mothers and infants. However, there is a dearth of literature on barriers and facilitators to adherence to pharmaceutical interventions among HEI who are retained in regular follow-up.
As part of a wider study that investigated barriers at various steps of the PMTCT cascade, we conducted a qualitative study to explore women’s ability to maintain their babies on CTX-p after they had been initiated at age six weeks. Although this study focused on CTX-p, the findings and implications do not relate to the issue of CTX-p provision alone but to the whole package of services provided to HIV-exposed infants along the PMTCT cascade.
The study was conducted at Mbare Clinic, Harare, during the period when the country was implementing WHO Option A (Zimbabwe transitioned to option B+ between 2013 and 2014). Between February to December 2011, we consecutively enrolled twenty willing women (who gave informed consent) and individually interviewed them in-depth. Eligible women were HIV positive and had babies who been started on CTX-p at age six weeks. In addition to CTX-p most babies were also being prescribed nevirapine prophylaxis (babies whose mothers were on ARVs for their own health were not prescribed nevirapine prophylaxis after six weeks of age). To identify HIV positive women, a cross-sectional survey was conducted during the antenatal period. A female study nurse conducted the survey and a female pharmacist who had been trained in social science methods conducted the in-depth interviews. Both study staff were external to the clinic system (i.e. they were not employed at the clinic and participants understood this).
Key areas of investigation during in-depth interviews
Key areas of investigation
Area of residence, marital status, family environment
Current health status
Physical strength and well-being following delivery
Feelings about HIV infection
History of HIV testing; feelings about HIV positive diagnosis
HIV care for the participant (mother)
What HIV care has been sought
Views of risk of mother-to-child transmission of HIV
Awareness/knowledge of risks; feelings about ability to protect the baby from infection
Views on cotrimoxazole prophylaxis
Knowledge/awareness of the importance of cotrimoxazole prophylaxis; views on CTX-p
Experience giving CTX-p to the baby
Barriers and facilitators to daily administration, including experience with prescription refills at the clinic
Awareness of other PMTCT services that baby is supposed to get
Probes on awareness
Any related issues that participant wanted to raise
Interviews were completed in 30—45 min. All were digitally recorded, transcribed, translated and analysed according to thematic analysis. Data analysis commenced as soon as data collection began: after each interview field notes were written with a view to identifying emerging themes. Following transcription and translation, analytic summaries were written for each interview using an approach which compared themes across participants, thus identifying similarities and deviant cases. A coding framework was developed and used for coding all the interviews. Coding was done by one researcher. Data handling and analysis was done using NVIVO 10 (qualitative data management software). In writing the report, thematic findings were illustrated using verbatim quotes which were selected on the basis of being representative of the quotes that related to a specific theme.
The study had ethical approval from Medical Research Council of Zimbabwe and University College London Research Ethics Committee. Written informed consent was obtained from all participants before interviews were conducted.
Description of participants
Out of 35 HIV positive women who were identified during the cross-sectional survey, 20 agreed to regular follow-up (and were interviewed at 4–5 months for this qualitative study); four were lost to follow-up before the 4–5 month period and 11 refused participation. Most refusers said they had no time. Non-participants did not differ from participants in terms of demographic characteristics.
Characteristics of interviewed participants
No of children
Timing of HIV diagnosis
During ANCa, at 3 months
During ANC, at 6 months
Previous pregnancy, 2009
During ANC, at 9 months
Previous pregnancy, 2003
During ANC, at 6 months
During ANC, at 8 months
2005 when she was sick
During ANC, at 6 months
During ANC, at 7 months
Previous pregnancy, 2009
VCTb, March 2010
During ANC, at 8 months
Tested at delivery
During ANC, at 8 months
2008, child was sick
During ANC, at 6 months
2007, when she was sick
Previous pregnancy, 2008
Barriers and facilitators to CTX-p adherence
Factors affecting women’s ability to keep their babies on CTX-p were grouped into 1) participant-level, 2) personal and community relationship level, and 3) health care system factors.
Participant knowledge, attitudes and beliefs
Desire for baby’s health
It causes you to constantly be alert; this is a baby I love, it’s a life…since the nurses who have the experience said it works so I have to make it possible. 24-year old married mother of two
Perceived health benefit
I have noticed that giving cotrimoxazole to the baby is helpful. If you keep giving it he does not suffer from colds, or diarrhoea like what other children do. 27-year old married mother of four
Cotrimoxazole is important because in the community I live there are some children who are not on medication, as I speak right now they have been to hospital a countless number of times. But with this child I have not been to hospital since delivery. 35 year old, married mother of four
When I was given her HIV (negative) test results that’s when I became more convinced that it is important to adhere to the given instructions. 24 year old married mother of two
Unfortunately, the converse was also true; perceived ineffectiveness of PMTCT interventions was associated with poor adherence. One woman stopped giving CTX-p when her baby tested HIV positive because she felt let down by the pharmaceutical interventions.
Aids to remembering
Because adherence was important to them, women reported that they used reminders to ensure that they did not forget. Most used phone alarms as aids to remembering. As many had already established routines for taking their own medicines (ARVs and CTX-p) they found it easy to fit the babies into these routines.
Acceptance of HIV results
…I thought, is this really my status? Does this really mean I am about to die? All my thoughts were about death. 24 year old married mother of two
I am putting effort to block it out of my mind. I heard some people say if you think about it too much, he-e-e your mind…you will get stressed and you will die quickly. So I pretend it doesn’t matter and ignore it… 29-year old divorced mother of three, sometimes didn’t collect prescription refills
Personal and community relationships
Personal and community relationships had a direct impact on adherence and were also important for acceptance of HIV status (which itself was associated with good adherence).
Relations with husbands/partners
Analysis of women’s accounts revealed that husbands/partners (16 participants were married) had a make-or-break influence on adherence. When looking at patterns in the women’s responses on level of adherence support they received from their husbands, it was clear that the less engaged in HIV issues a husband was, the less supportive for CTX-p. Three groups of husbands/partners were identified: 1) six men who provided the most support for adherence, 2) five who were not opposed to CTX-p but did not actively support it, and 3) five who opposed CTX-p.
With time I accepted it (her HIV status) because when I told him he received it well and we went for couples testing and he accepted it. 23 year old mother of one
I was expecting that he would start shouting at me, saying how come you have the disease, where did you get it from? But he was the one to say ahh it is possible to get a situation where the man has no disease and the woman has it…So because he did not get angry the situation did not become too difficult for me; because my husband showed me love, and said let’s remain together. Married mother of four, HIV sero-discordant relationship
This group of men also took an active part in ensuring that the baby was given CTX-p, e.g. by reminding the woman to give it and buying it from private pharmacies when the clinic had no supplies.
The second group consists of five men who had taken small steps towards confronting HIV in the family. All initially had negative reactions when the women disclosed their HIV results but with time they came to a point where they could discuss their family’s HIV care; they accepted the wife’s HIV status and were not opposed to the baby taking CTX-p, although they did not actively support it. Their main challenge was that they were not ready to share their own HIV status with their wives. All of them refused to go for couples counselling and testing and were sometimes hostile when this was suggested. There was the suggestion that the response to HIV was shaped by relationship dynamics and gender norms; it seemed that men were more accepting of their partner’s HIV status than the women expected. When explaining why her husband did not want to test for HIV, one participant said “He is afraid that if he tests positive I might leave him,” which is a paradox given that he had not left her when he discovered that she had HIV.
I explained that the cotrimoxazole is for prevention of infections. And he said ha-a my child is not going to keep taking medicines willy-nilly. 23-year old married mother of two
One participant tried to keep giving the CTX-p in secret but when her husband discovered it “He said if I kept giving cotrimoxazole he would take the baby away from me and give him to his mother.”
About a month after I delivered he suddenly asked me what the tablets (cotrimoxazole) were for. I explained to him and he became angry and said, “This is madness, these are all lies.” Then he took the tablets and threw them away.” 23-year old married mother of two
Relationships in the community: fear of HIV disclosure
“The challenge is people can come before I have given the medicine; then I will take the bottle outside… I can actually go and give the medicine in the toilet”. 23-year old married mother of one
This was particularly a challenge because of the unhygienic state of the shared toilets.
Sometimes it’s hard for me to collect the medicine because I might see someone I know; then it becomes incredibly difficult because I have not disclosed to anyone except my husband. 23-year old married mother of one
Health system factors
Counselling and education
She (the counsellor) helped me to accept it…she told me that I can give birth to a normal baby who can grow up without HIV. 23 year old mother of one
Of note, none of the women reported that they got this support/education from health care workers at the clinic, but they had either visited other centres or been counselled/educated by the study nurse.
Health system barriers to adherence included drug stock-outs and long queues at the clinic.
I stopped giving cotrimoxazole at that time. I could not give it as directed because I wanted it to last until the next appointment date. 41 year old divorced mother of five
Long queues at the clinic
We just know that a clinic appointment means that you will spend the whole day at the clinic; you will not even have time to wash the baby’s nappies. 41 year old married mother of 5
Related to this, women were scheduled to attend the clinic at different times for their own HIV care, which meant spending more days at the clinic.
The study revealed that adherence to CTX-p among HEI is influenced by the mother’s knowledge, attitudes and beliefs including perception of the importance and effectiveness of the intervention, desire for the baby’s health and acceptance of HIV status. Husbands were reported to have an important role, and the fear of HIV disclosure and subsequent stigma limited women’s ability to freely give CTX-p at home or to collect prescription refills. Health system factors such as provision of education and counselling and availability of drugs were important determinants of adherence. A significant strength of this study was the trust that participants had in the researcher/interviewer, whom they understood to be a health care worker who had a lot of information on HIV. As a result they openly discussed intimate details about their lives in the way they would with a trusted health care worker, sometimes in an effort to get more assistance/guidance on what services to seek for themselves or their babies and sometimes as to vent their feelings (in some instances the study team were the first people that the women had an in-depth discussion about their HIV infection with). The fact the interviewer was known to be external to the system at the clinic helped participants feel able to openly discuss challenges they faced with the clinic. This allowed a clearer insight into the participant’s situations. Although this study focused on CTX-p, the findings can be generalised to other pharmaceutical PMTCT interventions.
As expected, awareness of the rationale for giving CTX-p was associated with good adherence, which underlies the importance of educating mothers and carers about CTX-p/PMTCT interventions that have been prescribed. Perception of effectiveness is an important factor that motivated mothers: where the intervention was perceived to be ineffective, poor adherence ensued as was seen when one woman lost faith in all pharmaceutical interventions after her baby tested HIV positive. Clearly she had not properly understood the different roles of nevirapine and CTX-p and did not adequately appreciate the concept of risk reduction (as compared to risk cessation). It is likely important that women are given a more nuanced understanding of the likely effectiveness of nevirapine and CTX-p to ensure ongoing compliance in the event of transmission events. In the event of transmission, health care workers need to revisit this and also counsel about the importance of ongoing prophylactic treatment.
The extent of male partner’s engagement in HIV issues more generally was found to be a strong determinant of male support for CTX-p adherence. These findings add to the literature around importance of male involvement for PMTCT and provide an explanation of previous research findings that showed an increase in uptake of PMTCT services with couples testing and counselling [18–21]. Couples counselling improves the couple’s joint understanding of HIV and facilitates acceptance of HIV status and the family’s engagement in HIV treatment and prevention. Importantly, there was suggestion that men who had not received education/counselling thought HIV was emasculating, a finding that has been reported in other studies in Zimbabwe [22, 23]. It is clearly important to find ways to make couples testing and counselling acceptable to both parties. Education/messaging that emphasises how HIV testing can help a man achieve his ‘manly’ roles may be beneficial, e.g. accessing treatment after testing HIV positive will help maintain the man’s health and enable continued participation in masculine roles like providing for the family.
The fear of stigma was an important factor that limited women’s ability to give medicine at home or to collect prescription refills from the clinic. Of importance is the reminder that stigma also exists within marital relationships, hence the importance of stigma-reduction interventions cannot be overestimated. In addition to interventions to reduce stigma more generally, it may be worth considering if any small changes at the clinic could reduce the stigma associated with pharmacy refill- for example integration of services as described below. Stigma interventions have been classified into four categories: 1) informational approaches to give information on HIV disease, transmission and methods of reducing risk of acquisition, e.g. through mass media, educational lectures etc; 2) skill building, where potential perpetrators of stigma are given skills of how to interact with HIV positive people, 3) counselling/support to help HIV positive individuals to cope with the disease, e.g. in support groups, and 4) testimonials from people living with HIV [24, 25]. Many stigma-reduction activities are already going on in Zimbabwe, e.g. mass media campaigns, teaching about HIV in schools, and through the National Behaviour Change Programme, but more still needs to be done to achieve communities with low stigma levels. Stigma reduction is particularly important for PMTCT programs: mathematical modelling estimates that failure to access PMTCT services as a result of stigma may account for more than half (53 %) of all perinatal HIV transmissions, and that scale-up of stigma reduction interventions has the potential to avert 33 % of vertical infections [26, 27].
The health care system was seen to play an important role in adherence—stock-outs of cotrimoxazole resulted in many missed CTX-p doses. Findings in the larger study indicated that there was more than enough stock of cotrimoxazole nationally, but that logistic and training challenges interrupted the supply chain. Training local clinic staff on supply chain management will alleviate these challenges. The long waiting times at the clinic were also reported to be problematic, particularly since the mothers had to wait separately for their own HIV care. Integration of mother/baby HIV care might help reduce this burden on mothers. Still on the subject of integration, although the clinic has taken steps to prevent HIV disclosure by integrating HIV services within the general chronic diseases clinic, many people still perceive the integrated unit as an HIV clinic, which limits women’s ability to freely collect prescription refills for their babies. Integration of all services into the general outpatient clinic might be one way of solving this challenge.
The qualitative study was conducted in a small group of women in Mbare. Although the findings were insightful and consistent across participant accounts, they cannot be generalised to the whole Zimbabwean population. Information on husband/partner attitudes towards CTX-p adherence was obtained from the interviewed women, not the husbands themselves.
The study highlights that adherence knowledge and desire to protect one’s child from HIV is insufficient to overcome the familial and structural barriers to maintaining CTX-p. Improving adherence among HEI will require interventions to improve male engagement with HIV issues and to increase acceptance of couples counselling and testing, reduce HIV stigma in communities and ensure continuous supply of drugs.
We would like to thank Dr Mungofa and management at Harare City Health Department for allowing us to conduct the study at one of their clinics. We would also like to thank the women in Mbare, Harare, who volunteered to participate in this study.
We thank Wellcome Trust for funding this study.
Wellcome Trust through a fellowship given to ELS.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Marinda E, Humphrey JH, Iliff PJ, Mutasa K, Nathoo KJ, Piwoz EG, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J. 2007;26(6):519–26.View ArticlePubMedGoogle Scholar
- Koyanagi A, Humphrey JH, Ntozini R, Nathoo K, Moulton LH, Iliff P, et al. Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy. Pediatr Infect Dis J. 2011;30(1):45–51.View ArticlePubMedGoogle Scholar
- Kuhn L, Kasonde P, Sinkala M, Kankasa C, Semrau K, Scott N, et al. Does severity of HIV disease in HIV-infected mothers affect mortality and morbidity among their uninfected infants? Clin Infect Dis. 2005;41(11):1654–61.View ArticlePubMedPubMed CentralGoogle Scholar
- Reikie BA, Adams RC, Leligdowicz A, Ho K, Naidoo S, Ruck CE, et al. Altered innate immune development in HIV-exposed uninfected infants. J Acquir Immune Defic Syndr. 2014;66(3):245–55.View ArticlePubMedPubMed CentralGoogle Scholar
- Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones SL. HIV-exposed uninfected children: a growing population with a vulnerable immune system? Clin Exp Immunol. 2014;176(1):11–22.View ArticlePubMedPubMed CentralGoogle Scholar
- World Health Organisation. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants. Geneva, Switzerland: WHO; 2010.Google Scholar
- World Health Organisation. Programmatic update: Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. In: WHO, editor. WHO guidelines. Geneva, Switzerland: WHO; 2012.Google Scholar
- World Health Organisation. Co-trimoxazole prophylaxis for HIV exposed and HIV infected infants and children. Practical Approaches to implementation and scale up. In: Practical Approaches to implementation and scale up. Geneva: WHO; 2009.Google Scholar
- Wettstein C, Mugglin C, Egger M, Blaser N, Vizcaya LS, Estill J, et al. Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis. AIDS. 2012;26(18):2361–73.View ArticlePubMedPubMed CentralGoogle Scholar
- Braitstein P, Katshcke A, Shen C, Sang E, Nyandiko W, Ochieng VO, et al. Retention of HIV-infected and HIV-exposed children in a comprehensive HIV clinical care programme in Western Kenya. Trop Med Int Health. 2010;15(7):833–41.View ArticlePubMedPubMed CentralGoogle Scholar
- Sibanda EL, Weller IV, Hakim JG, Cowan FM. The magnitude of loss to follow-up of HIV-exposed infants along the prevention of mother-to-child HIV transmission continuum of care: a systematic review and meta-analysis. AIDS. 2013;27(17):2787–97.View ArticlePubMedPubMed CentralGoogle Scholar
- Zimbabwe Ministry of Health and Child Welfare. Zimbabwe Ministry of Health and Child Welfare: HIV Estimates Report 2007. In: Estimates Reports. Harare: Government of Zimbabwe; 2008.Google Scholar
- Zimbabwe Ministry of Health and Child Welfare. HIV Estimates report, 2010. In: MoHCW, editor. Estimates Report. Harare, Zimbabwe: MoHCW; 2011.Google Scholar
- Cowan FM, Buzdugan R, McCoy SI, Martz TE, Watadzaushe C, Dirawo J, et al. What happens to the babies? PMTCT outcomes among a community sample of HIV-exposed infants from Zimbabwe. In: 7th IAS Conference on HIV pathogenesis, treatment and prevention. Kuala Lumbur, Malaysia: IAS 2013; 2013.Google Scholar
- Braitstein P, Songok J, Vreeman RC, Wools-Kaloustian KK, Koskei P, Walusuna L, et al. “Wamepotea” (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to follow-up from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr. 2011;57(3):E40–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Donahue MC, Dube Q, Dow A, Umar E, Van Rie A. They have already thrown away their chicken: barriers affecting participation by HIV-infected women in care and treatment programs for their infants in Blantyre, Malawi. AIDS Care. 2012;24(10):1233–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Wachira J, Middlestadt SE, Vreeman R, Braitstein P. Factors underlying taking a child to HIV care: implications for reducing loss to follow-up among HIV-infected and -exposed children. SAHARA J. 2012;9(1):20–9.View ArticlePubMedGoogle Scholar
- Farquhar C, Kiarie JN, Richardson BA, Kabura MN, John FN, Nduati RW, et al. Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. J Acquir Immune Defic Syndr. 2004;37(5):1620–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Msuya SE, Mbizvo EM, Hussain A, Uriyo J, Sam NE, Stray-Pedersen B. Low male partner participation in antenatal HIV counselling and testing in northern Tanzania: implications for preventive programs. AIDS Care. 2008;20(6):700–9.View ArticlePubMedGoogle Scholar
- Becker S, Mlay R, Schwandt HM, Lyamuya E. Comparing couples’ and individual voluntary counseling and testing for HIV at antenatal clinics in Tanzania: a randomized trial. AIDS Behav. 2010;14(3):558–66.View ArticlePubMedGoogle Scholar
- Peltzer K, Mlambo M, Phaswana-Mafuya N, Ladzani R. Determinants of adherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Gert Sibande district in South Africa. Acta Paediatr. 2010;99(5):699–704.PubMedGoogle Scholar
- Skovdal M, Campbell C, Madanhire C, Mupambireyi Z, Nyamukapa C, Gregson S. Masculinity as a barrier to men’s use of HIV services in Zimbabwe. Global Health. 2011;7(1):13.View ArticlePubMedPubMed CentralGoogle Scholar
- Skovdal M, Campbell C, Nyamukapa C, Gregson S. When masculinity interferes with women’s treatment of HIV infection: a qualitative study about adherence to antiretroviral therapy in Zimbabwe. J Int AIDS Soc. 2011;14:29.View ArticlePubMedPubMed CentralGoogle Scholar
- Sengupta S, Banks B, Jonas D, Miles MS, Smith GC. HIV interventions to reduce HIV/AIDS stigma: a systematic review. AIDS Behav. 2011;15(6):1075–87.View ArticlePubMedPubMed CentralGoogle Scholar
- Brown L, Macintyre K, Trujillo L. Interventions to reduce HIV/AIDS stigma: what have we learned? AIDS Educ Prev. 2003;15(1):49–69.View ArticlePubMedGoogle Scholar
- Turan JM, Nyblade L. HIV-related stigma as a barrier to achievement of global PMTCT and maternal health goals: a review of the evidence. AIDS Behav. 2013;17(7):2528–39.View ArticlePubMedGoogle Scholar
- Watts C, Zimmerman C, Eckhaus T, Nyblade L. Working paper: modelling the impact of stigma on HIV and AIDS programmes: preliminary projections for mother-to-child transmission. Washington DC: International Centre for Research on Women and London School of Hygiene and Tropical Medicine; 2010.Google Scholar